Abstract
Purpose: We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of KRAS in non–small-cell lung cancer (NSCLC). Methods: KRAS mutation was determined in blinded fashion. Exploratory analyses were performed to characterize relationships between mutation status and subtype and survival outcomes using a multivariable Cox model. Results: Among 1,543 patients (763 OBS, 780 ACT), 300 had KRAS mutations (codon 12, n = 275; codon 13, n = 24; codon 14, n = 1). In OBS patients, there was no prognostic difference for overall survival for codon-12 (mutation v wild type [WT] hazard ratio [HR] = 1.04; 95% CI, 0.77 to 1.40) or codon-13 (HR = 1.01; 95% CI, 0.47 to 2.17) mutations. No significant benefit from ACT was observed for WT-KRAS (ACT v OBS HR = 0.89; 95% CI, 0.76 to 1.04; P = .15) or codon-12 mutations (HR = 0.95; 95% CI, 0.67 to 1.35; P = .77); with codon-13 mutations, ACT was deleterious (HR = 5.78; 95% CI, 2.06 to 16.2; P < .001; interaction P = .002). There was no prognostic effect for specific codon-12 amino acid substitution. The effect of ACT was variable among patients with codon-12 mutations: G12A or G12R (HR = 0.66; P = .48), G12C or G12V (HR = 0.94; P = .77) and G12D or G12S (HR = 1.39; P = .48; comparison of four HRs, including WT, interaction P = .76). OBS patients with KRAS-mutated tumors were more likely to develop second primary cancers (HR = 2.76, 95% CI, 1.34 to 5.70; P = .005) but not ACT patients (HR = 0.66; 95% CI, 0.25 to 1.75; P = .40; interaction, P = .02). Conclusion: KRAS mutation status is not significantly prognostic. The potential interaction in patients with codon-13 mutations requires validation. At this time, KRAS status cannot be recommended to select patients with NSCLC for ACT.
Original language | English (US) |
---|---|
Pages (from-to) | 2173-2181 |
Number of pages | 9 |
Journal | Journal of Clinical Oncology |
Volume | 31 |
Issue number | 17 |
DOIs | |
State | Published - Jun 10 2013 |
Bibliographical note
Funding Information:Supported by la Ligue Nationale Contre le Cancer (France), le Programme National d’Excellence Spécialisé cancer du poumon de l’Institut National du Cancer (INCa) (France), the National Cancer Institute (United States), the Canadian Cancer Society Research Institute (Canada), and an unrestricted grant from Sanofi.
Funding Information:
Supported by la Ligue Nationale Contre le Cancer (France), le Programme National d'Excellence Sp?cialis? cancer du poumon de l?Institut National du Cancer (INCa) (France), the National Cancer Institute (United States), the Canadian Cancer Society Research Institute (Canada), and an unrestricted grant from Sanofi. We thank Ni Liu (Princess Margaret Hospital) for technical assistance in sample analysis.
Publisher Copyright:
© 2013 by American Society of Clinical Oncology.